Market Size of Middle East and Africa Insulin Delivery Devices Industry
Study Period | 2017- 2028 |
Base Year For Estimation | 2022 |
Forecast Data Period | 2023 - 2028 |
Market Size (2023) | USD 1.9 Billion |
Market Size (2028) | USD 2.20 Billion |
CAGR (2023 - 2028) | 2.99 % |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Middle East And Africa Insulin Delivery Devices Market Analysis
The Middle East and Africa Insulin Delivery Devices Market size is expected to grow from USD 1.90 billion in 2023 to USD 2.20 billion by 2028, at a CAGR of 2.99% during the forecast period (2023-2028).
The COVID-19 pandemic has substantially impacted the Middle East and Africa Insulin Delivery Devices Market. Type-1 diabetes patients are impacted more during Covid-19. People with diabetes are having a weak immune system so, with COVID-19, the immune system gets weaker very fast. People with diabetes will have more chances to get into serious complications rather than normal people. The manufacturers of Insulin delivery devices have taken care during COVID-19 to deliver insulin delivery devices to diabetes patients with the help of local governments. Novo Nordisk stated on their website that “Since the start of COVID-19, our commitment to patients, our employees and the communities where we operate has remained unchanged, we continue to supply our medicines and devices to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19.” Doctors around the world suggested diabetes patients should check their diabetes levels more often to be careful and the intake of medicine has increased, which lead to an increase in the usage of insulin delivery devices.
An insulin infusion pump works as an alternative to the traditional system of daily injections or an insulin pen. Insulin infusion pumps reduce the large swings in blood glucose levels, lessen pain, and deliver more accurately than injections. The scheduling of meal timings is not required when using pumps. This makes infusion pumps more user-friendly for patients. Insulin therapy is also known as continuous subcutaneous insulin infusion (CSII). It is an efficient and flexible method of insulin delivery.
Technological advancements have increased over the period in Insulin delivery devices for safer and more accurate administration of insulin. In 2021, Medtronic launched an Extended infusion set that leverages advanced materials that help reduce insulin preservative loss and maintains insulin flow and stability. The set is compatible with all MiniMed 600 and 700 series insulin pumps. The new tubing connector improves the physical and chemical stability of insulin, reliability of infusion site performance, and reduces the risk of infusion set occlusion. In addition to the new infusion set, the Medtronic Extended reservoir is also tested and approved to keep insulin stable and safely used for up to 7 days.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.